TABLE 3.

The combination Ad-HIVenv/rev priming/gp140ΔV2 boosting regimen elicits broadly reactive antibodies able to neutralize heterologous R5-tropic primary HIV-1 clade B isolates

Chimpanzee no./Ad doseNeutralization (% reduction in RLU after first/after second gp140 boost)a
BalJR-FLBx08610169211681196ADA
Replicating Ad
    271/10745/2621/023/780/012/4510/055/3758/59
    363/10792/4393/099/6796/050/1092/087/770/0
    A163/10715/880/810/960/900/850/820/970/80
    386/10835/304/042/240/021/150/00/6232/36
    182D/10835/600/070/860/023/420/083/950/50
Nonreplicating Ad
    376/1088/140/00/680/00/360/030/365/23
    360/1080/90/150/720/1925/120/055/3363/77
    373/10945/7738/5853/8327/2451/5439/3684/9679/82
    A003/1090/00/00300/00/50/031/3126/44
    A136/1090/00/09/400/00/50/00/3721/22
  • a Sera obtained 2 weeks after each boost with HIVSF162 gp140ΔV2 were evaluated at 1:15 dilutions. Positive results (>50% reduction in relative luciferase units [RLU]) are in boldface.